Devin Lowe

Associate Professor

Texas Tech University Health Sciences Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Devin Lowe is an Associate Professor at Texas Tech University Health Sciences Center in the United States. His research focuses on cancer immunotherapy, particularly in relation to dendritic cell vaccines, antibody-drug conjugates, and tumor microenvironment interactions. Recent articles authored by Professor Lowe emphasize therapeutic strategies aimed at enhancing immune responses against various cancers, including melanoma and colorectal cancer.

Articles (9)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (3)

Walter Storkus

Professor

University of Pittsburgh

UNITED STATES

View details

Dipongkor Saha

California Northstate University College of Pharmacy

UNITED STATES

View details

Ninh La-Beck

Texas Tech University Health Sciences Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Devin Lowe

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1.

Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein.

Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression.

Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection.

Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity.

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Pathogenetic Features and Current Management of Glioblastoma.

Antibody-drug conjugates: an evolving approach for melanoma treatment.

Dendritic cell vaccine therapy for colorectal cancer.

Collaborators (3)

Walter Storkus

Dipongkor Saha

Ninh La-Beck

Make your next move.